Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

BACKGROUND: The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 studies of patients with PsA were...

Descripción completa

Detalles Bibliográficos
Autores principales: Helliwell, Philip, Coates, Laura C., FitzGerald, Oliver, Nash, Peter, Soriano, Enrique R., Elaine Husni, M., Hsu, Ming-Ann, Kanik, Keith S., Hendrikx, Thijs, Wu, Joseph, Kudlacz, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235208/
https://www.ncbi.nlm.nih.gov/pubmed/30373651
http://dx.doi.org/10.1186/s13075-018-1739-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235208/
https://www.ncbi.nlm.nih.gov/pubmed/30373651
http://dx.doi.org/10.1186/s13075-018-1739-0

Ejemplares similares